NIPA2P2

Across TCGA pan-cancer cohorts, NIPA2P2 RNA is linked to patient survival in 8 of 34 cancer types, making it the most broadly survival-associated NIPA2P2 data layer.

The strongest signal is observed in pancreatic adenocarcinoma (PAAD), where higher NIPA2P2 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated NIPA2P2 expression acts as an unfavorable survival marker, although some lineages such as OV show a favorable association.

PAAD, KIRC, and PCPG are the cancer types where NIPA2P2 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PAAD	DFS	Tertile	All	0.231	0.480	.012	63	view →
KIRC	DFS	Tertile	IV	0.127	0.619	.008	36	view →
PCPG	OS	Tertile	All	0.078	0.955	<.001	36	view →
UCEC	DFS	Tertile	All	0.748	0.902	.002	36	view →
OV	DFS	Tertile	III,IV	0.285	0.140	.022	36	view →
SARC	DFS	Tertile	All	0.135	0.617	<.001	30	view →
READ	OS	Tertile	III,IV	0.328	0.751	.003	27	view →
UCS	OS	Tertile	All	0.185	0.686	.034	18	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

NIPA2P2–PAAD (DFS)

Open the PAAD breakdown →